{ "model": "qwen/qwen3.6-35b-a3b", "started_at": "2026-05-19T22:00:44.079Z", "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n last 90 days totaling ≥ $500K\n • +3 pts if CEO is among the buyers\n • +3 pts if CFO is among the buyers\n • +2 pts if total purchases > $5M\n • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n • +3 pts if it's in the manager's top-3 positions\n • 2 pts for politician STOCK Act recent buy\n • +1 pt if multiple unrelated members bought within 30 days\n • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n and flow_strength ∈ {moderate, strong}\n • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n • 1 pt: large OI building at a defended price level\n • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n • 8 pts: pending product launch / FDA / contract milestone in horizon\n • 5 pts: recent guidance raise (last 90 days)\n • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n to this name in $)\n Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n earnings)\n • 4 pts: EV/EBITDA ≥ 30% below sector median\n • 4 pts: FCF yield ≥ 7% with stable FCF\n • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n • 5 pts: ROIC ≥ 15% (or trending there)\n • 5 pts: gross margin expanding ≥ 3pp YoY\n • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n • 3 pts: above both 50DMA and 200DMA\n • 4 pts: 12-1 month price return positive AND beating sector\n • 2 pts: RSI 14 in 40-65 zone\n • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n \"core\" — market_cap > $5B. Standard methodology sizing.\n \"asymmetric\" — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n bets lose money or go to zero; the few that work pay\n for the rest. Position sizing is far more conservative\n to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n CORE risk_class:\n ≥ 80 Publish, confidence 5, position size cap 4-5%\n 70-79 Publish, confidence 4, position size cap 2.5-3.0%\n 60-69 Publish, confidence 3, position size cap 1.5-2.0%\n 50-59 Skip unless catalyst <30d + insider cluster\n < 50 Skip\n\n ASYMMETRIC risk_class — strict sizing:\n ≥ 80 Publish, confidence 5, position size cap 1.5%\n 70-79 Publish, confidence 4, position size cap 1.0%\n 60-69 Publish, confidence 3, position size cap 0.5%\n < 60 Skip (no exception; small caps need a clear catalyst)\n Structure must be long_stock (options structures are wrong shape for\n moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n • Going-concern audit qualification\n • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n • Customer concentration > 30%\n • Convertible/warrant overhang creating dilution > 10% of float\n • Accounting irregularities (restatements, auditor changes)\n • Avg daily volume < $5M (liquidity gate)\n • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n verdict='promising' → long_stock | csp (for asymmetric long)\n verdict='range_bound_or_income' → cc | strangle | csp on pullback\n (DON'T default to long_stock — Scout\n already said this isn't an asymmetric\n long. Look at IV elevated → strangle;\n stock at 52w high, fundamentals healthy\n → cc against implicit long; pullback\n thesis with cash → csp)\n verdict='bearish_setup' → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n long_stock — multi-quarter asymmetric thesis, IV not elevated, want\n full upside participation\n csp — bullish, want to own at strike, IV elevated, ann yield ≥15%\n cc — range-bound or mildly bullish, IV elevated, on top of long\n stock leg, if-called return ≥15% ann\n strangle — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n put. Need: comfortable owning at put_strike, no parabolic\n upside expectation. Ann yield ≥12%. Compute and emit\n breakeven_high (call_strike + total_premium) and\n breakeven_low (put_strike - total_premium).\n naked_put — same setup as CSP but using margin. ~2x yield, margin call\n risk. Only for margin-equipped accounts. Note explicitly.\n naked_call — bearish setup with elevated IV. UNCAPPED loss if rally.\n Confidence ceiling 4 (Compliance enforces). Requires\n explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n \"skip\": false,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"draft\": {\n \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n \"symbol\": \"TICKER\",\n \"company\": \"Full name\",\n \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n \"risk_class\": \"core\" | \"asymmetric\",\n \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n \"thesis_short\": \"1 sentence — why this trade exists.\",\n \"thesis_long\": [\n \"Opening paragraph framing the setup.\",\n \"## Catalyst\",\n \"Detailed catalyst narrative.\",\n \"## Why the market is mispricing this\",\n \"Edge explanation, citing dossier facts.\",\n \"## Numbers\",\n \"- Bullet 1 with concrete numbers from the dossier\",\n \"- Bullet 2\",\n \"## Risk\",\n \"Honest description of what could go wrong.\"\n ],\n \"structure\": {\n \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n \"long_stock\": { \"entry_zone_low\": , \"entry_zone_high\": , \"shares_per_unit\": 100 },\n \"csp\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"if_assigned_basis\": },\n \"cc\": { \"underlying_basis\": , \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"if_called_return_pct\": },\n \"strangle\": { \"call_strike\": , \"put_strike\": , \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": , \"put_premium_target\": , \"total_premium_target\": , \"breakeven_high\": , \"breakeven_low\": , \"annualized_yield_pct\": , \"max_loss_note\": \"...\" },\n \"naked_put\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss_per_contract\": , \"margin_estimate_per_contract\": , \"warning\": \"...\" },\n \"naked_call\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n },\n \"entry\": {\n \"price_at_idea\": ,\n \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n },\n \"exit\": {\n \"target_price\": ,\n \"time_horizon_months\": ,\n \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n },\n \"risk\": {\n \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n },\n \"sources\": [\n { \"label\": \"...\", \"url\": \"...\" }\n ],\n \"confidence\": <1-5, conservative>,\n \"analyst\": \"research-desk\",\n \"scout_model\": \"minimax/minimax-m2.7\",\n \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n \"devils_advocate_verdict\": null\n }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.", "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n \"symbol\": \"OMCL\",\n \"company\": \"Omnicell, Inc.\",\n \"investigation_summary\": \"The investigation found no open-market insider purchases (P-codes) — all four Form 4s filed May 19 report F-codes (RSU tax withholding by the CEO, CFO, CAO, and CLO) or S-codes (Rule 10b5-1 scheduled sales). Nnamdi Njoku's April RSU grant (A-code, $0 exercise) is compensation equity, not a discretionary buy. The filing cluster triggering this investigation was routine vesting-related activity misidentified as insider conviction. Q1 2026 earnings beat expectations with 15% revenue growth and margin expansion, prompting analyst target raises to $55-$70, but the stock has already rallied ~20% from its October low and sits near the upper portion of its 52-week range with limited apparent upside vs. consensus targets.\",\n \"verdict\": \"range_bound_or_income\",\n \"confidence_in_data\": 4,\n \"structure_hints\": [\n \"cc\"\n ],\n \"business_snapshot\": \"Omnicell provides medication management automation (automated dispensing cabinets, central pharmacy robotics, IV compounding systems) and SaaS/Expert services to hospital/health system customers under long-term contracts, plus outpatient/adherence solutions. The company generated $1.23B in FY2025 revenue with ~15% yoy growth, transitioning toward recurring service revenues (~44% of Q1 2026 sales). Gross margins improved to 45.3% in Q1 2026 vs. 41.2% a year prior as operating leverage from automation investments materialized. The company carries $737M in goodwill (acquisition-related intangibles amortizing over 10-30 years), indicating a heavy M&A history that depresses reported ROIC to ~1.3%. Q1 2026 non-GAAP EPS of $0.55 beat the ~$0.33 estimate by 66%, with management raising full-year guidance — but this catalyst has already moved the stock significantly.\",\n \"scoring_inputs\": {\n \"smart_money\": {\n \"insider_open_market_purchases_90d\": [],\n \"insider_open_market_total_usd_90d\": 0,\n \"distinct_insider_buyers_90d\": 0,\n \"ceo_buy_present\": false,\n \"cfo_buy_present\": false,\n \"material_insider_selling_90d_usd\": 0,\n \"notable_13f_holders\": [\n \"pending — v2\"\n ],\n \"politician_recent_buys\": [\n \"pending — v2\"\n ]\n },\n \"catalyst\": {\n \"next_earnings_date\": \"2026-07-29 (est. based on ~90d cadence)\",\n \"recent_eps_surprise_pattern\": \"Q1 2026: EPS $0.55 vs est $0.33 (+66%); Q4 2025: EPS $0.40 vs est $0.50 (-19%); pattern is mixed with recent strong beat and guidance raise\",\n \"guidance_raise_in_last_90d\": true,\n \"named_catalysts\": [\n {\n \"type\": \"earnings\",\n \"description\": \"Q1 2026 beat + full-year guide raise (April 28, 2026)\",\n \"date_or_window\": \"Apr 28, 2026\",\n \"source_urls\": [\n \"https://www.sec.gov/Archives/edgar/data/926326/000092632626000009/omcl-20260428.htm\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"guidance\",\n \"description\": \"Full-year FY2026 EPS and revenue guidance raised post-Q1 beat\",\n \"date_or_window\": \"Q2 2026 reporting window (est. July 29)\",\n \"source_urls\": [\n \"https://www.sec.gov/Archives/edgar/data/926326/000092632626000012/omcl-20260331.htm\"\n ],\n \"directional_bias\": \"bullish\"\n }\n ]\n },\n \"mispricing\": {\n \"forward_pe\": 19.96,\n \"sector_median_forward_pe\": null,\n \"ev_to_ebitda\": 26.2,\n \"sector_median_ev_to_ebitda\": null,\n \"fcf_yield_pct\": 5.6,\n \"sotp_gap_pct\": null,\n \"narrative\": \"At ~$44, OMCL trades at 20x forward earnings — reasonable for a healthcare automation name growing revenue mid-teens with margin expansion. But it is near the upper end of its 52-week range ($26.85-$55), with analyst consensus price targets ($61 mean) implying only ~30% further upside versus recent stock appreciation of >50% from October lows. No compelling SOTP discount or FCF yield premium to suggest mispricing.\"\n },\n \"quality\": {\n \"roic_pct\": 1.3,\n \"gross_margin_trend_pp_yoy\": \"+4pp (Q1 2026: 45.3% vs Q1 2025: 41.2%)\",\n \"net_debt_to_ebitda\": null,\n \"balance_sheet_grade\": \"B\"\n },\n \"technical\": {\n \"above_50dma\": true,\n \"above_200dma\": true,\n \"rsi_14\": 62,\n \"macd_recent_bullish_cross\": false,\n \"12_1_momentum_vs_sector_pct\": null\n }\n },\n \"price_context\": {\n \"last_close\": 43.82,\n \"ytd_return_pct\": 5.2,\n \"from_52w_high_pct\": 19.9\n },\n \"filings_reviewed\": [\n {\n \"form\": \"10-K\",\n \"filed\": \"2026-02-26\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/926326/000092632626000006/omcl-20251231.htm\",\n \"key_takeaways\": [\n \"FY2025 revenue $1.23B (+14.9% YoY), transition toward recurring SaaS/services; gross margin 43.9%; heavy goodwill ($737M) from acquisitions depresses ROIC; debt of ~$202M vs $239M cash; notes healthcare policy headwinds (Medicaid cuts, 340B program pressure); no open-market P-code insider purchases visible in filing\"\n ]\n },\n {\n \"form\": \"10-Q\",\n \"filed\": \"2026-05-06\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/926326/000092632626000012/omcl-20260331.htm\",\n \"key_takeaways\": [\n \"Q1 2026: Revenue $309.9M (+15% YoY), gross margin 45.3% (+4pp YoY), net income $11.4M vs loss of $7.0M in Q1 2025; operating leverage from cost discipline; deferred revenues up to $275M (growing backlog); remaining performance obligations $383M provide revenue visibility\"\n ]\n }\n ],\n \"options_context\": {\n \"expiries_examined\": [\n \"2026-06-18\",\n \"2026-08-21\",\n \"2026-11-20\",\n \"2026-12-18\"\n ],\n \"iv_summary\": \"ATM IV at Jun 18 expiry is approximately 60-65%; OTM puts show IV ~64% (40P), ATM-ish puts show ~58%, ITM calls show elevated IV ~82% (50C)\",\n \"notable_skew_or_flow\": \"Put/call ratio on near-term flow is elevated (3.0 on Jun 18) but driven by open interest in protective $40 put rather than new whale positioning. Top OI on calls at $45 strike with 57 contracts — a modest covered-call target above current spot.\"\n },\n \"competitive_landscape\": \"Omnicell competes with Becton Dickinson (Pyxis), Swisslog/P Cardinal Health, and Emergent Software for hospital automation; the space has seen consolidation but no imminent competitive threats. Healthcare customers are sticky under multi-year GPO agreements.\",\n \"key_risks\": [\n \"Debt/EBITDA leverage in a reimbursement-pressured environment ($910B Medicaid cuts estimated)\",\n \"Goodwill amortization suppresses reported earnings — adjusted figures needed for true profitability assessment\",\n \"Convertible notes due 2029 (~$168M carrying value) require refinancing risk monitoring\",\n \"340B program regulatory changes could impact health-system customers' capital budgets\",\n \"No open-market insider conviction: recent Form 4 cluster was RSU vesting, not discretionary buying\",\n \"Stock near upper end of 52-week range with limited apparent margin of safety\"\n ],\n \"what_the_market_might_be_missing\": \"The Q1 gross margin expansion (+400bps YoY) may be underappreciated — the market is anchored on OMCL as a low-margin healthcare IT name rather than an emerging high-leverage automation platform. However, without insider buying conviction and with the stock already having run significantly, this edge is speculative at current levels.\",\n \"anti_signals_present\": [\n \"dilution\",\n \"low_liquidity\"\n ],\n \"sources\": [\n {\n \"label\": \"10-K 2025\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/926326/000092632626000006/omcl-20251231.htm\"\n },\n {\n \"label\": \"Q1 2026 10-Q\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/926326/000092632626000012/omcl-20260331.htm\"\n },\n {\n \"label\": \"Form 4 Lipps May 19, 2026\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/926326/000122755626000008/xslF345X06/form4-05192026_050515.xml\"\n },\n {\n \"label\": \"Form 4 Manley May 19, 2026\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/926326/000192872726000010/xslF345X06/form4-05192026_050518.xml\"\n },\n {\n \"label\": \"Q1 Earnings 8-K\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/926326/000092632626000009/omcl-20260428.htm\"\n }\n ],\n \"unfetched_signals\": [\n \"13f_deltas\",\n \"politician_trades\",\n \"sentiment_score\"\n ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude ... reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.", "completions": [ { "ts": "2026-05-19T22:01:38.451Z", "raw_content": "The user wants me to score the dossier for OMCL (Omnicell, Inc.) based on a specific rubric and decide whether to skip or draft a trade idea.\n\nLet's evaluate the dossier against the rubric:\n\nA. SMART-MONEY CLUSTER (max 25)\n- No open-market insider purchases (0 pts)\n- No CEO/CFO buys (0 pts)\n- No >$5M purchases (0 pts)\n- No notable 13F initiation (0 pts)\n- No politician buys (0 pts)\n- Penalty: No material insider selling > buying mentioned (0 pts)\nScore: 0\n\nB. OPTIONS FLOW / UOA (max 10)\n- No whale call blocks mentioned. (0 pts)\n- IV skew: ATM IV 60-65%, OTM puts ~64%. Not clearly bullish call IV > put IV. (0 pts)\n- Net dollar bias: Not mentioned. (0 pts)\n- Large OI at defended level: Top OI on calls at $45 (modest). (0 pts)\n- Penalty: Put/call ratio elevated (3.0) but driven by protective OI, not new whale positioning. (0 pts)\nScore: 0\n\nC. CATALYST (max 25)\n- Next earnings: July 29, 2026. (Within 90 days? Depends on current date, but let's assume it's close. The dossier says \"Q1 2026 earnings beat expectations... prompting analyst target raises...\". Wait, Q1 2026 earnings already happened in April. The dossier says \"next_earnings_date: 2026-07-29\". So it's within 90 days. But last 4 quarters' EPS surprise > 0%? Q4 2025 was -19%. So not 4 quarters > 0%. (0 pts)\n- Pending product launch/FDA/contract: None mentioned. (0 pts)\n- Recent guidance raise: Yes, Q1 2026 beat + full-year guide raise. (5 pts)\n- Quantifiable sector tailwind: None mentioned. (0 pts)\nScore: 5\n\nD. MISPRICING (max 15)\n- Forward P/E: 19.96. Sector median null. Can't score. (0 pts)\n- EV/EBITDA: 26.2. Sector median null. Can't score. (0 pts)\n- FCF yield: 5.6%. < 7%. (0 pts)\n- SOTP gap: null. (0 pts)\nScore: 0\n\nE. QUALITY (max 15)\n- ROIC: 1.3%. < 15%. (0 pts)\n- Gross margin expanding ≥ 3pp YoY: +4pp YoY. (5 pts)\n- Net debt / EBITDA: null. (0 pts)\nScore: 5\n\nF. MOMENTUM/TECHNICAL (max 10)\n- Above 50DMA & 200DMA: Yes. (3 pts)\n- 12-1 month return positive & beating sector: null. (0 pts)\n- RSI 14 in 40-65 zone: 62. (2 pts)\n- MACD bullish cross: false. (0 pts)\nScore: 5\n\nTotal Score: 0 + 0 + 5 + 0 + 5 + 5 = 20.\n\nRisk Class: market_cap not explicitly given, but OMCL is typically a mid/small cap (~$2.5B-$3B). The dossier says \"pending — v2\" for 13F/politician. I'll assume market cap ≤ $5B -> asymmetric, or > $5B? Actually, Omnicell's market cap is around $2.8B. So \"asymmetric\". But score is 20, which is < 60. Skip regardless.\n\nAnti-signal gates:\n- \"dilution\" (convertible notes due 2029 ~$168M)\n- \"low_liquidity\" (Avg daily volume < $5M?)\nThe dossier explicitly lists `anti_signals_present: [\"dilution\", \"low_liquidity\"]`. This triggers the skip gate.\n\nEdge Check:\nThe dossier says: \"without insider buying conviction and with the stock already having run significantly, this edge is speculative at current levels.\" The market already priced in the Q1 beat and guide raise. No asymmetric upside.\n\nConclusion: Skip.\nScore: 20.\nReason: No insider conviction, already-ran catalyst, elevated valuation relative to quality metrics (ROIC 1.3%), and anti-signal gates (dilution, low liquidity) make this a mediocre, over-extended setup with no clear income structure edge at current levels.\n\nLet's double check the scoring rubric to ensure I didn't miss anything.\nA: 0\nB: 0\nC: 5 (guidance raise)\nD: 0\nE: 5 (gross margin)\nF: 5 (above DMA, RSI)\nTotal: 20.\n\nMatches skip criteria (<60 for asymmetric, <50 for core). Anti-signal gates present.\nI will output the skip JSON.\nCheck format:\n{\n \"skip\": true,\n \"score\": 20,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 5\n },\n \"reason\": \"The dossier shows no insider conviction, an already-priced-in catalyst, and weak quality metrics (ROIC 1.3%). Anti-signal gates for dilution and low liquidity further invalidate the setup, making it a mediocre, over-extended trade with no clear structural edge.\"\n}\nAll constraints met. Output matches exactly.\nProceed. \nOne minor thing: The prompt says \"Cap at 25 even if components add to more\" for Catalyst. I gave 5. Correct.\n\"Cap at 15\" for Mispricing. I gave 0. Correct.\n\"Cap at 10\" for Technical. I gave 5. Correct.\nTotal 20.\nReady. \nOutput matches requested JSON structure.\nNo extra text.\nDone. \nSelf-Correction/Verification during thought:\nWait, does the dossier mention market cap? It doesn't explicitly, but I can assume it's small/mid cap. Regardless, score is 20, which is < 60 for asymmetric and < 50 for core. So skip is mandatory.\nAnti-signal gates are explicitly present: `[\"dilution\", \"low_liquidity\"]`. The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I will note that they apply.\nEverything is solid.\nOutput matches exactly.✅\nProceeds. \nOutput Generation. \n```json\n{\n \"skip\": true,\n \"score\": 20,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 5\n },\n \"reason\": \"The dossier shows no insider conviction, an already-priced-in catalyst, and weak quality metrics (ROIC 1.3%). Anti-signal gates for dilution and low liquidity further invalidate the setup, making it a mediocre, over-extended trade with no clear structural edge.\"\n}\n```\nMatches requirements. No markdown fences per instruction? Wait, instruction says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\" I will output raw JSON.\nDone. \nProceeds. \n[Output Generation] -> *Self-Correction/Refinement during generation prep*: I will ensure the JSON is strictly valid and matches the schema exactly. The prompt says \"No surrounding prose, no markdown fences.\" I will output just the JSON string.\nAll good. \nProceeds. \n[Output] -> *Proceeds*\n\n\n{\n \"skip\": true,\n \"score\": 20,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 5\n },\n \"reason\": \"The dossier shows no insider conviction, an already-priced-in catalyst, and weak quality metrics (ROIC 1.3%). Anti-signal gates for dilution and low liquidity further invalidate the setup, making it a mediocre, over-extended trade with no clear structural edge.\"\n}", "cleaned_content": "{\n \"skip\": true,\n \"score\": 20,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 5\n },\n \"reason\": \"The dossier shows no insider conviction, an already-priced-in catalyst, and weak quality metrics (ROIC 1.3%). Anti-signal gates for dilution and low liquidity further invalidate the setup, making it a mediocre, over-extended trade with no clear structural edge.\"\n}", "tool_calls": null, "finish_reason": "stop" } ], "tool_results": [], "final_message": "{\n \"skip\": true,\n \"score\": 20,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 5\n },\n \"reason\": \"The dossier shows no insider conviction, an already-priced-in catalyst, and weak quality metrics (ROIC 1.3%). Anti-signal gates for dilution and low liquidity further invalidate the setup, making it a mediocre, over-extended trade with no clear structural edge.\"\n}", "tool_calls_total": 0, "walltime_ms": 54373, "stop_reason": "stop", "completed_at": "2026-05-19T22:01:38.452Z" }